Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ib Study of a Soluble Beta-glucan Odetiglucan in Combination with a CD40 Agonist (CDX-1140) in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During First-Line Chemotherapy

Summary

The purpose of this study is to evaluate the safety and feasibility of odetiglucan and CDX-1140 as maintenance therapy in patients with metastatic pancreatic adenocarcinoma.

General Information

NCT#: NCT05484011
Study ID: PGG-PAN2111
Trial Phase: Phase I

Trial Sponsor: HiberCell, Inc
Therapies Used in This Trial: CDX-1140

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search